My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 233

    1.

    Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.

    Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE.

    Ann Intern Med. 1993 Mar 15;118(6):407-13.PMID: 8439113 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.

    Cubeddu LX, Pendergrass K, Ryan T, York M, Burton G, Meshad M, Galvin D, Ciociola AA.

    Am J Clin Oncol. 1994 Apr;17(2):137-46.PMID: 8141105 [PubMed - indexed for MEDLINE]Related articles

    3.

    Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.

    Beck TM.

    Semin Oncol. 1992 Dec;19(6 Suppl 15):20-5.PMID: 1485178 [PubMed - indexed for MEDLINE]Related articles

    4.

    A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.

    Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR.

    Ann Oncol. 1996 Nov;7(9):945-52.PMID: 9006746 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.

    Buser KS, Joss RA, Piquet D, Aapro MS, Cavalli F, Haefliger JM, Jungi WF, Bauer J, Obrist R, Brunner KW, et al.

    Ann Oncol. 1993 Jun;4(6):475-9.PMID: 8353089 [PubMed - indexed for MEDLINE]Related articles

    6.

    Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.

    Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS, Hortobagyi GN.

    J Clin Oncol. 1991 Jul;9(7):1268-74.PMID: 1828499 [PubMed - indexed for MEDLINE]Related articles

    7.

    Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.

    Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C.

    J Clin Oncol. 1998 Feb;16(2):754-60.PMID: 9469367 [PubMed - indexed for MEDLINE]Related articles

    8.

    Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.

    Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C.

    Cancer J Sci Am. 1998 Jan-Feb;4(1):52-8.PMID: 9467047 [PubMed - indexed for MEDLINE]Related articles

    9.

    Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

    DiBenedetto J Jr, Cubeddu LX, Ryan T, Kish JA, Sciortino D, Beall C, Eisenberg PD, Henderson C, Griffin D, Wentz A.

    Clin Ther. 1995 Nov-Dec;17(6):1091-8.PMID: 8750400 [PubMed - indexed for MEDLINE]Related articles

    10.

    Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.

    Beck TM, York M, Chang A, Navari R, Harvey WH, Meshad M, Griffin D, Wentz A.

    Cancer Invest. 1997;15(4):297-303.PMID: 9246149 [PubMed - indexed for MEDLINE]Related articles

    11.

    Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life.

    Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J.

    Clin Ther. 1996 May-Jun;18(3):508-18. Corrected and republished in: Clin Ther. 1996 Jul-Aug;18(4):778-88. PMID: 8829027 [PubMed - indexed for MEDLINE]Related articles

    12.

    Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group.

    Davidson NG, Paska W, Van Belle S, Goedhals L, McQuade B, McRae J.

    Oncology. 1997 Sep-Oct;54(5):380-6.PMID: 9260599 [PubMed - indexed for MEDLINE]Related articles

    13.

    Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.

    Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, et al.

    J Clin Oncol. 1995 Sep;13(9):2408-16.PMID: 7666101 [PubMed - indexed for MEDLINE]Related articles

    14.

    Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life.

    Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J.

    Clin Ther. 1996 Jul-Aug;18(4):778-88.PMID: 8879903 [PubMed - indexed for MEDLINE]Related articles

    15.

    Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.

    Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn AL.

    J Clin Oncol. 1990 Oct;8(10):1721-7.PMID: 2145400 [PubMed - indexed for MEDLINE]Related articles

    16.

    Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.

    Stewart A, McQuade B, Cronje JD, Goedhals L, Gudgeon A, Corette L, Froger X, Tubiana-Hulin M, Laplaige P, Roberts JT, et al.

    Oncology. 1995 May-Jun;52(3):202-10.PMID: 7715904 [PubMed - indexed for MEDLINE]Related articles

    17.

    Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.

    Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W.

    J Clin Oncol. 1996 Aug;14(8):2242-9.PMID: 8708713 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.

    Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M, Pater J.

    J Clin Oncol. 1994 May;12(5):1050-7.PMID: 8164029 [PubMed - indexed for MEDLINE]Related articles

    19.

    Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.

    Alvarez O, Freeman A, Bedros A, Call SK, Volsch J, Kalbermatter O, Halverson J, Convy L, Cook L, Mick K, et al.

    J Pediatr Hematol Oncol. 1995 May;17(2):145-50.PMID: 7749764 [PubMed - indexed for MEDLINE]Related articles

    20.

    Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).

    Joss RA, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, Aapro MS, Thürlimann B.

    Ann Oncol. 1994 Mar;5(3):253-8.PMID: 8186174 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity